Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Diamyd Therapeutics AB
Age
10–20
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening
Fasting C-peptide level at time of screening above 0.1 nmol/L
Elevated GAD65 antibodies (GADA) at time of screening
Male and female patients between 10 and 20 years of age
You may not be if
Treatment with immunosuppressants or any anti-diabetic medications other than insulin
A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)
Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine
Participation in other clinical trials with a new chemical entity within the previous 3 months
Pregnancy or planned pregnancy within 1 year after the last Diamyd dose
Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study
Clareo Health | A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
